Europe, Malta (Commonwealth Union) – Health authorities have confirmed that the Mpox case reported last week has been identified as Clade II, following comprehensive laboratory testing and analysis.
Mpox, previously known as Monkeypox, is caused by the Monkeypox virus, which is categorized into two distinct clades: Clade I and Clade II.
Clade I, primarily found in Central Africa, is associated with more severe illness and higher mortality rates. Due to its seriousness, the World Health Organisation (WHO) declared Clade I a Public Health Emergency of International Concern (PHEIC) in August 2024.
In contrast, Clade II is less severe and has a much lower mortality rate. This clade is responsible for the ongoing global outbreak that began in 2022, which has spread mainly through human-to-human sexual transmission. Up until 2023, Malta investigated 35 cases linked to this global outbreak, with the current case, the first reported in 2024, also falling under Clade II.
The authorities indicated that another Mpox case has been confirmed in a resident of the country, who contracted the virus through sexual activity in Malta. The individual is currently in stable condition and does not need hospitalization. The patient has been placed in isolation, and contact tracing is in progress to prevent additional spread. Further testing is underway to determine the specific Clade of the Mpox virus involved in this case.
The health authorities of Malta stated that they are dedicated to closely keeping track of the situation and will issue updates when required. They encouraged the public to stay informed and adhere to the recommended guidelines to protect their health and safety.
WHO declared Mpox as a global health emergency last month. Many cases of Mpox were reported across the world in the last few weeks.
Once identified, infected individuals must be isolated to prevent transmission. This may involve hospitalization in severe cases or self-isolation at home for milder cases. Contacts of infected persons are generally traced and monitored for symptoms, with vaccination offered to high-risk contacts as post-exposure prophylaxis. Public awareness campaigns are essential in controlling the spread of Mpox. Clear communication about the virus, its symptoms, and transmission routes can help reduce stigma and encourage individuals to seek care if they suspect infection.
